Plasminogen activators in multiple sclerosis lesions implications for the inflammatory response and axonal damage

Brain

Volumn 124, Issue 10, 2001, Pages 1978-1988

  Gveric, Djordje ^a   Hanemaaijer, Roeland ^b   Newcombe, Jia ^a   Van Lent, Natascha A ^b   Sier, Cornelis F M ^c   Cuzner, M Louise ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b TNO   (Netherlands)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Axon; ELISA; Matrix metalloproteases; Multiple sclerosis; Plasminogen activators

Indexed keywords

BIOCHEMICAL MARKER; FIBRINOGEN; GELATINASE B; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN LOCALIZATION;

EID: 0034774402     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/124.10.1978     Document Type: Article

References (42)

1. Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury
2. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases
3. Tissue plasminogen activator gene expression in multiple sclerosis brain tissue
4. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke
5. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours
6. Prognostic significance of proteolytic-enzymes in human brain tumours
7. uPA, uPAR, PAI-I: Key intersection of proteolytic, adhesive and chemotactic highways?
8. Plasminogen activators in synovial fluid and plasma from patients with arthritis
9. Plasminogen activation in synovial tissues: Differences between normal, osteoarthritis, and rheumatoid arthritis joints
10. Determination of gelatinase-A (MMP-2) activity using a novel immunocapture assay
11. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
12. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes
13. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin
14. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution
15. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
16. Cytokine-mediated activation of cultured CNS microvessels: A system for examining antigenic modulation of CNS endothelial cells, and evidence for long-term expression of the adhesion protein e-selectin
17. The glial scar and central nervous system repair
18. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein
19. Tissue urokinase-type plasminogen activator receptor levels in breast cancer
20. Tenascin-R and C in multiple sclerosis lesions: Relevance to extracellular matrix remodelling
21. Insulin-like growth factors and binding proteins in multiple sclerosis plaques
22. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: Saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels
23. Microglial apoptosis induced by chromogranin A is mediated by mitochondrial depolarisation and the permeability transition but not by cytochrome c release
24. Co-operative effect of TNF alpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity
25. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis
26. Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques
27. Real-time imaging of the axonal transport of granules containing a tissue plasminogen activator green fluorescent protein hybrid
28. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo
29. Distribution of glial fibrillary acidic protein in gliosed human white matter
30. Monoclonal antibody 14E recognizes an antigen common to human oligodendrocytes, Schwann cells, Bergmann glia, and a subpopulation of reactive glia
31. Monoclonal antibody to human 66 000 molecular weight plasminogen activator from melanoma cells: Specific enzyme inhibition and one step affinity purification
32. Tissue-type plasminogen activator and its inhibitor in rat aorta. Effect of endotoxin
33. Release of plasminogen activator and a calcium-dependent metalloprotease from cultured sympathetic and sensory neurons
34. Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system
35. The plasminogen activation system in rheumatoid arthritis
36. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury
37. Plasminogen activators and their interaction with the extracellular matrix in neural development, plasticity and regeneration
38. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells
39. Vitronectin and integrin vitronectin receptor localization in multiple sclerosis lesions
40. Axonal transection in the lesions of multiple sclerosis
41. Clinical implications of the involvement of tPA in neuronal cell death
42. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells